Clinical Trials Logo

Community-Acquired Pneumonia clinical trials

View clinical trials related to Community-Acquired Pneumonia.

Filter by:

NCT ID: NCT04724044 Completed - Sepsis Clinical Trials

Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia

ACCESS
Start date: January 25, 2021
Phase: Phase 3
Study type: Interventional

Traditional management of community-acquired pneumonia (CAP) relies on the prompt administration of antimicrobials that target the most common causative pathogens. Retrospective analysis of observational clinical studies in CAP showed that the addition of macrolides to standard antibiotic therapy conferred a significant survival benefit. The proposed benefit of macrolides is coming from their anti-inflammatory mode of action. An RCT that proves the attenuation of the high inflammatory burden of the host with CAP after addition of clarithromycin in the treatment regimen is missing. This RCT is aiming to prove that addition of oral clarithromycin to a β-lactam rapidly attenuates the high inflammatory burden of the host in CAP.

NCT ID: NCT04686331 Completed - Clinical trials for Community-acquired Pneumonia

Accuracy of Lung Injury Biomarkers in the Initial Investigation of Patients With Suspected Pneumonia

Start date: March 1, 2021
Phase:
Study type: Observational

The aim of this study is to investigate the diagnostic and prognostic value of surfactant protein D, Krebs von den Lungen (KL-6), and Chitinase-3-like protein 1 (YKL-40) in the initial investigation of patients hospitalized with suspected pneumonia. This to improve the diagnosis of pneumonia, contribute to a more rapid and accurate antibiotic treatment, and assess disease severity to predict short-term and long-term mortality in community-acquired pneumonia patients.

NCT ID: NCT04350502 Completed - Clinical trials for Community-acquired Pneumonia

Pharmacokinetics and Pleural Fluid Penetration of Amoxicillin and Clavulanic Acid in Patients With Pleural Infections

PK-plèvre
Start date: April 4, 2020
Phase: N/A
Study type: Interventional

The incidence of pleural infection is increasing worldwide since the last two decades. Antibiotics are one of the cornerstones of the treatment of this disease and must be associated to a correct evacuation of the pleural effusion. Data concerning the pleural diffusion of antibiotics currently used in community acquired pleural infection are scarce. The main objective of this study is to evaluate the pleural pharmacokinetic of amoxicillin and clavulanic acid in patients with a complicated pleural infection (patients who need a chest tube insertion).

NCT ID: NCT04198571 Completed - Clinical trials for Community Acquired Pneumonia

Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries

Start date: May 17, 2020
Phase:
Study type: Observational

MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated with Zinforo® (ceftaroline fosamil) in a Usual Care Setting

NCT ID: NCT04160260 Completed - Clinical trials for Community-acquired Pneumonia

Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia

Start date: November 28, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics of an oral omadacycline dosing regimen in the treatment of adults with CABP.

NCT ID: NCT03774953 Completed - Clinical trials for Community-acquired Pneumonia

The Effect of Protein Supplement on Lean Body Mass in Patients With Pneumonia

CAPprotein
Start date: January 15, 2019
Phase: N/A
Study type: Interventional

The purpose of this clinical trial is to reduce the patient's loss of lean body mass by protein supplementation during hospitalization and 60 days after hospital discharge. Also, the study aims to reduce the risk of readmission to the hospital due to relapse or complications and thereby improving the overall health for the patients. The intervention group will receive protein supplementation during hospitalization and after discharge, while the control group will continue their normal diet.

NCT ID: NCT03696303 Completed - Clinical trials for Community-acquired Pneumonia

Determination of the Utility of Pfizer's Pneumococcal Urine Antigen Test in Children 5 Years of Age or Younger With Community Acquired Pneumonia in Guatemala

Start date: March 13, 2019
Phase:
Study type: Observational

This prospective case-control study aims to evaluate the utility and establish laboratory thresholds for a multi-serotype urine antigen test for the diagnosis of pneumococcal community acquired pneumonia in children 5 years of age or younger in Guatemala.

NCT ID: NCT03672994 Completed - Healthy Clinical Trials

Exhaled Breath Metabolomic Biomarkers in the Acutely Breathless Patient

EMBER
Start date: February 2, 2017
Phase:
Study type: Observational

An acute study carried out across three acute admissions units within Leicestershire. The study is aimed at discovery and validation of volatile organic compounds (VOCs) in exhaled breath. Participants will be recruited and tested within 24 hours of admission and once recovered, up to 6 months following discharge.

NCT ID: NCT03475732 Completed - Sepsis Clinical Trials

Pharmacokinetics of XueBiJing in Patients With Sepsis

Start date: March 18, 2018
Phase: N/A
Study type: Interventional

Pharmacokinetics and disposition of XueBiJing compounds in patients with sepsis

NCT ID: NCT03474991 Completed - Clinical trials for Community-acquired Pneumonia

KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP

KIDS-STEP
Start date: October 28, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to concurrently evaluate whether adjunct treatment with corticosteroids in children hospitalized with CAP is more effective in terms of the proportion of children reaching clinical stability and whether such adjunct treatment is no worse in terms of CAP relapse.